Ep. 367 - FDA, obesity targets and the rise of DACs
From BioCentury This Week · · 30 min
This plays from the publisher's own server. We do not host a copy.
Description
Marty Makary wasn’t the only official on the outs (https://www.biocentury.com/article/659451) at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses (https://www.biocentury.com/article/659523) who’s in, who’s out and what’s next at FDA — and why the changes may mean more conservative decision-making at the agency in the near term. BioCentury’s analysts also discuss the new obesity targets (https://www.biocentury.com/article/659471) that came to light at last week’s annual meeting of the European Congress on Obesity, the market for biotech IPOs, and the emergence of degrader-antibody conjugates (https://www.biocentury.com/article/659413). DACs pair the tissue-targeting logic of antibody-drug conjugates (ADCs) with the catalytic activity of protein degraders. 3C Therapeutics is the latest entrant (https://www.biocentury.com/article/659374) to the field, pitching its TriCore platform as a modular backbone for DAC generation. This episode of the BioCentury podcast is brought to you by Jeito Capital (https://www.jeito.life/en/home/).
View full story: https://www.biocentury.com/article/659510
#FDA #ObesityDrugDevelopment #BiotechIPO #DACs #Biopharma
00:01 - Sponsor Message: Jeito Capital 02:53 - FDA Leadership Shakeup 10:35 - Obesity Target Hunt 16:07 - Biotech IPOs 20:02 - Degrader-antibody Conjugates 28:42 - Serif: Non-viral DNA
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)